MetLife Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.11M | Sell |
10,562
-93
| -0.9% | -$18.4K | 0.01% | 1028 |
|
|
2025
Q4 | $2.01M | Sell |
10,655
-438
| -4% | -$84.2K | 0.01% | 1075 |
|
|
2025
Q3 | $1.97M | Sell |
11,093
-294
| -3% | -$43.7K | 0.01% | 1095 |
|
|
2025
Q2 | $1.29M | Buy |
11,387
+1,095
| +11% | +$117K | 0.01% | 1181 |
|
|
2025
Q1 | $1.08M | Sell |
10,292
-190
| -2% | -$21.5K | 0.01% | 1326 |
|
|
2024
Q4 | $1.12M | Buy |
10,482
+542
| +5% | +$61.3K | 0.01% | 1352 |
|
|
2024
Q3 | $995K | Hold |
9,940
| – | – | 0.01% | 1389 |
|
|
2024
Q2 | $838K | Buy |
9,940
+1,143
| +13% | +$91K | 0.01% | 1440 |
|
|
2024
Q1 | $643K | Hold |
8,797
| – | – | ﹤0.01% | 1543 |
|
|
2023
Q4 | $628K | Hold |
8,797
| – | – | ﹤0.01% | 1558 |
|
|
2023
Q3 | $527K | Hold |
8,797
| – | – | ﹤0.01% | 1600 |
|
|
2023
Q2 | $634K | Buy |
8,797
+699
| +9% | +$52.4K | ﹤0.01% | 1542 |
|
|
2023
Q1 | $596K | Sell |
8,098
-519
| -6% | -$36.9K | ﹤0.01% | 1536 |
|
|
2022
Q4 | $576K | Sell |
8,617
-5,196
| -38% | -$338K | ﹤0.01% | 1553 |
|
|
2022
Q3 | $742K | Hold |
13,813
| – | – | 0.01% | 1360 |
|
|
2022
Q2 | $769K | Hold |
13,813
| – | – | 0.01% | 1363 |
|
|
2022
Q1 | $969K | Buy |
13,813
+4,894
| +55% | +$355K | 0.01% | 1347 |
|
|
2021
Q4 | $859K | Hold |
8,919
| – | – | 0.01% | 1193 |
|
|
2021
Q3 | $775K | Sell |
8,919
-13,339
| -60% | -$1.03M | 0.01% | 1266 |
|
|
2021
Q2 | $1.82M | Sell |
22,258
-416
| -2% | -$34.6K | 0.02% | 915 |
|
|
2021
Q1 | $2.16M | Sell |
22,674
-1,769
| -7% | -$167K | 0.02% | 838 |
|
|
2020
Q4 | $1.52M | Sell |
24,443
-649
| -3% | -$37K | 0.01% | 948 |
|
|
2020
Q3 | $1.49M | Sell |
25,092
-522
| -2% | -$35.6K | 0.02% | 850 |
|
|
2020
Q2 | $1.79M | Sell |
25,614
-1,544
| -6% | -$97.9K | 0.02% | 767 |
|
|
2020
Q1 | $1.23M | Sell |
27,158
-973
| -3% | -$55.1K | 0.02% | 813 |
|
|
2019
Q4 | $1.83M | Sell |
28,131
-3,217
| -10% | -$215K | 0.02% | 847 |
|
|
2019
Q3 | $1.95M | Sell |
31,348
-2,222
| -7% | -$140K | 0.02% | 799 |
|
|
2019
Q2 | $2.39M | Sell |
33,570
-1,321
| -4% | -$97.3K | 0.03% | 732 |
|
|
2019
Q1 | $2.74M | Sell |
34,891
-795
| -2% | -$60.2K | 0.03% | 668 |
|
|
2018
Q4 | $3.02M | Buy |
35,686
+20,728
| +139% | +$2.21M | 0.04% | 541 |
|
|
2018
Q3 | $2.56M | Hold |
14,958
| – | – | 0.03% | 756 |
|
|
2018
Q2 | $1.93M | Hold |
14,958
| – | – | 0.02% | 802 |
|
|
2018
Q1 | $1.54M | Hold |
14,958
| – | – | 0.02% | 859 |
|
|
2017
Q4 | $1.28M | Buy |
+14,958
| New | +$1.3M | 0.01% | 935 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
MetLife Investment Management's LGND Position: Q1 2026 in Review
MetLife Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 0.87% in Q1 2026, selling an estimated $18.4K and leaving 10,562 shares worth $2.11M. The position accounts for 0.01% of the portfolio, ranked #1028.
MetLife Investment Management first reported a position in LGND in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.02M in Q4 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- MetLife Investment Management held 10,562 shares of Ligand Pharmaceuticals worth $2.11M as of Q1 2026.
- MetLife Investment Management sold 93 Ligand Pharmaceuticals shares in Q1 2026, an estimated $18.4K.
- Ligand Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1028 holding.
- MetLife Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Ligand Pharmaceuticals position peaked at $3.02M in Q4 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.